YourBio Health’s Post

🌟 Super early bird discount alert! 🌟 Don't miss out on the opportunity to join us at the 7th Annual MarketsandMarkets Real-World Evidence and Life Sciences Analytics Conference, happening on October 17th - 18th, 2024 in Boston! Our conference is set to bring together a diverse range of experts, leaders, and stakeholders, all converging to share insights and perspectives on crucial industry points. With a focus on best practices, attendees will engage in discussions aimed at enhancing decision-making processes. Real-World Evidence (RWE) solutions stand at the forefront of innovation, offering invaluable tools for both industrial and academic researchers. Through digitally connected platforms, RWE enables continuous patient monitoring and facilitates the organization and evaluation of clinical data for regulatory submissions. However, as the field of RWE research continues to evolve, it becomes increasingly evident that certain gaps remain unexplored. That's why our conference aims to provide guidance and foster consensus on essential annotations, ultimately driving the effective utilization of real-world data. Take advantage of this chance to stay ahead in this dynamic field by grabbing your super early bird discount now! Come to Boston for two days of unmatched learning, networking, and collaboration. Don't wait - register today and enjoy savings! DM or reach out to me at [email protected] to know more! Note: Discounts are valid only until 25th May for first 30 registrants. To learn more about the conference: https://lnkd.in/d4kqnDf4 #RWE #LifeSciences #Analytics #Boston #EarlyBirdSpecial #realworlddata #realworldevidence #healthcare #advancedmedicine #lifesciencesanalytics #lifesciences #conference2024 #healthcare #pharma #marketsandmarkets #RWDL2024 #bostonconference2024 #rwdlboston2024

Collaboration = Success 💡 🌟 Read how partnerships across companies, #healthcare and #Academia are creating impactful solutions in the #Genomicsnation 2023 report 🤝 ➡️ https://ow.ly/mZIp50QgpI0 ✍️ Published in collaboration with Medicines Discovery Catapult and Wellcome Sanger Institute #GenomicsCollaboration #HealthcareSuccess

🎙 New Episode of The Emerging Biotech Leader 🎙 “Safety doesn’t live outside of you. It’s not a yellow ribbon that you wear in hospitals that says, ‘it’s patient safety week.’ It’s not a sign in your office that says, ‘this is patient safety month.’ It’s a consequence of how we approach our work on a day-to-day and hour to hour basis. And it’s by definition, therefore, an emergent property of who we are and how we engage with our work.” Dr. Jason A Campagna By textbook definition, safety is the condition of being protected from or unlikely to cause danger, risk, or injury. To help us navigate this topic from the lens of the biotech sector, we have two new voices on the show: Amit Patel, PharmD Patel, Senior Vice President at SSI Strategy and Dr. Jason Campagna, Chief Medical Officer at Q32 Bio Inc. Bio, Inc. 🎧 Listen & Subscribe here: https://lnkd.in/dtKA4MXv

Good Morning. The latest BHI E-newsletter is now live. This week we have news and stories, including: 💰 Gaithersburg's Salubris Biotherapeutics secures $35 million in financing and updates on pipeline progress. 🏭 US Pharmacopeia. (USP) joins Biomedical Advanced Research and Development Authority (BARDA)'s BioMaP-Consortium to enhance national preparedness for public health emergencies. 💊 DrFirst, Inc. acquires Myndshft Technologies to revolutionize medication management, bridging medical and pharmacy benefits for improved access and affordability. 💉 Novavax supplies updated COVID-19 vaccine to private healthcare providers in the UK, offering a protein-based non-mRNA option for the 2024 vaccination season. 🩺 Clinical trial demonstrates the effectiveness of novel cell therapy treatments in immune-compromised pediatric patients, showing significant improvement over standard care. Children's National Hospital 🏢 BioPharmaDive interviews Joel Marcus on research clusters and the biotech sector's recovery, emphasizing the importance of established hubs like Boston and San Francisco. ⏰ TIME discusses the potential of biotech's advancements, highlighting personalized therapies, lab-grown meat, and AI-driven breakthroughs. 🔬 AMPEL BioSolutions selected as a member of ARPA-H's nationwide health innovation network, aiming to accelerate the commercialization of health breakthroughs for better outcomes. All this plus upcoming events, BHI offerings, and more at https://lnkd.in/esZFMAWY

🚀I'm thrilled to announce that I'll be speaking at the upcoming DIA Global Meeting, taking place in San Diego, US, between 16-20 June, on a topic that's close to my heart: Digital Biomarkers as Clinical Endpoints - The Road to Regulatory Acceptability. 💡In an era where technology and healthcare are increasingly intertwined, digital biomarkers offer groundbreaking potential to revolutionize clinical trials and patient care. This session will explore how we can harness these innovative tools to meet regulatory standards and improve health outcomes worldwide. 🔍In my speech, I'll be diving deep into the current landscape of digital biomarkers, with the focus on Europe, and exploring the path towards wider regulatory acceptance. I'll be sharing real-world examples and @Bayer’s perspective to help us navigate this exciting new frontier in clinical research. 🙏I'm especially grateful to Susan Awad and Lina AlJuburi for inviting me to share the industry insights on this critical topic. Digital biomarkers have the potential to revolutionize clinical trials, offering a more objective and efficient way to measure treatment effects. However, their regulatory acceptance is still evolving. 🌐 If you're interested in the future of clinical trials and the potential of digital biomarkers, then be sure to join the conference! I look forward to a stimulating discussion and the opportunity to connect with fellow leaders in the healthcare industry. hashtag #digitalhealth hashtag #clinicaltrials hashtag #regulatoryaffairs hashtag #globalhealthcare hashtag #digitalbiomarkers hashtag #DIA2024 https://ow.ly/XxFR50QwsWt Steve Berman – BIO, Deputy Vice President, Science and Regulatory Affairs Strategy Gul Erdemli – Novartis, Global Program Regulatory director Anindita (Annie) Saha – FDA Associate Director for Strategic Initiatives, Digital Health Center of Excellence Marwan Fathallah, President and Chief Executive Officer, DIA Global Ania Mitan, DIA Susan Benedetti, MSOL, DES, Senior Project Manager, Global Annual Meeting Maureen Lamplugh, Retired, Former Annual Meeting Program Manager, DIA Christian Rommel, Bayer AG Stefan Oelrich, Bayer AG Elena Popa, Bayer AG Antoine Manson, Bayer AG

Are you attending Probiota 2024? I’d love to connect with you! Let’s discuss how Atlantia Clinical Trials can speed up your products Go-To-Market with robust scientific proof that holds up under scrutiny. See you in Milan! #probiota2023 #MicrobiomeResearch #ClinicalTrials #InnovationInScience

@Roche and @(RED) collaborate to power access to healthcare in low-and-middle income countries. The partnership is driven to develop sustainable health systems that include strengthened laboratories for testing, with trained healthcare professionals available to serve more patients. Over the last two decades, significant progress has been made in boosting access to testing and treatment services. This is the product of like-minded partners identifying innovative funding models and working with governments to implement them. Together with #(RED), we are formulating innovative funding solutions and scaling up testing where it is most needed. Partnerships are the key to realising our Universal healthcare Access Goals. It can be done! #RocheAfrica #RED #RocheDiagnostics #LeadershipForGood #EndAIDS #RocheImpact See our partnership impact video: https://lnkd.in/geFWQg6p

What an amazing way to close the year in which we celebrate our centenary… having our CEO Lars Fruergaard Jørgensen as person of the Year 2023 by Financial Times! Very proud of our journey as a company on behalf of the wellbeing of people living with serious chronic diseases! 💙 #novonordisk #drivingchangeforgenerations #novonordisk100

Chapter One. To me, that is what January represents – the beginning of a new story that we all get to write together. As we kickstart the new year, I’m excited to begin the first chapter of what promises to be a yearlong story of people coming together to help our patients and their loved ones lead happier, healthier lives; Of innovation that pushes the boundaries of science; Of teams dedicated to bringing that science to the patients who need it most; Of all of us, collectively, working to uplift each other, our industry and our society at large. At Novartis US, the stories we write would not be possible without our teams who bring them to life – a dedicated group of colleagues working tirelessly to magnify our impact in a meaningful and significant manner, in service of our patients. As we look ahead to where we can make a difference, let’s also be mindful of the platform we have to create opportunities for others who will carry our stories forward. Using our seat at the table to set the table for others – that is how our stories build and grow. What stories will you bring to life this year? Share in the comments below ⤵️ #Novartis #ReimagineMedicine

What an experience at the BIO International Convention in San Diego this past week. Our CEO, Zach Gobst, shared some powerful insights on why APAC is a prime destination for complex and challenging clinical trials.  One key insight: “Designing recruitment around engagement is crucial. In APAC, you can work with patients and physicians who prioritize your research, paired with a local staff model to navigate study nuances for high-quality results.” Tailoring our approach at the country and local level is a key element of Leapcure’s approach. It ensures better study outcomes and a deeper connection with the broader community. Let’s all continue to innovate and make a global impact. #clinicaltrials #APAC #patientengagement #BIO2024 #leapcure